This company has been acquired
TPTX Stock Overview
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Turning Point Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$76.01 |
| 52 Week High | US$82.20 |
| 52 Week Low | US$23.77 |
| Beta | -0.19 |
| 1 Month Change | 1.58% |
| 3 Month Change | 114.96% |
| 1 Year Change | 18.90% |
| 3 Year Change | 45.39% |
| 5 Year Change | n/a |
| Change since IPO | 163.01% |
Recent News & Updates
Recent updates
Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report
Jul 21We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth
Mar 23
Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth
Dec 06The Take On Turning Point Therapeutics
Dec 03Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts
Aug 15Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business
Aug 04Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer
Jun 17Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 08Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?
Feb 26Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study
Jan 29Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher
Jan 22
We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn
Jan 13Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers
Dec 28Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?
Dec 15Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer
Dec 08Turning Point Therapeutics EPS beats by $0.12, beats on revenue
Nov 12Shareholder Returns
| TPTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | 3.7% | 1.2% |
| 1Y | 18.9% | -1.0% | 23.7% |
Return vs Industry: TPTX exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: TPTX exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| TPTX volatility | |
|---|---|
| TPTX Average Weekly Movement | 34.2% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TPTX's share price has been volatile over the past 3 months.
Volatility Over Time: TPTX's weekly volatility has increased from 20% to 34% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 267 | Athena Countouriotis | www.tptherapeutics.com |
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company’s lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors.
Turning Point Therapeutics, Inc. Fundamentals Summary
| TPTX fundamental statistics | |
|---|---|
| Market cap | US$3.81b |
| Earnings (TTM) | -US$342.31m |
| Revenue (TTM) | US$1.01m |
3,776x
P/S Ratio-11.1x
P/E RatioIs TPTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TPTX income statement (TTM) | |
|---|---|
| Revenue | US$1.01m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.01m |
| Other Expenses | US$343.32m |
| Earnings | -US$342.31m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | -33,959.03% |
| Debt/Equity Ratio | 0% |
How did TPTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/17 14:27 |
| End of Day Share Price | 2022/08/16 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Turning Point Therapeutics, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Arlinda Lee | Canaccord Genuity |
| Paul Choi | Goldman Sachs |